Short telomere length predicts nonrelapse mortality after stem cell transplantation for myelodysplastic syndrome.
Myllymäki M, Redd R, Reilly CR, Saber W, Spellman SR, Gibson CJ, Hu ZH, Wang T, Orr EH, Grenier JG, Chen MM, Steensma DP, Cutler C, De Vivo I, Antin JH, Neuberg D, Agarwal S, Lindsley RC.
Myllymäki M, et al.
Blood. 2020 Dec 24;136(26):3070-3081. doi: 10.1182/blood.2020005397.
Blood. 2020.
PMID: 33367544
Free PMC article.
Clinical Trial.
Allogeneic hematopoietic stem cell transplantation is the only potentially curative treatment for patients with myelodysplastic syndrome (MDS), but long-term survival is limited by the risk of transplant-related complications. Short telomere length, mediated …
Allogeneic hematopoietic stem cell transplantation is the only potentially curative treatment for patients with myelodysplastic syndrome (MD …